Classifications: antibiotic; quinolone; Therapeutic: antibiotic
Pregnancy Category: C
200 mg, 400 mg tablets; 0.3% ophthalmic solution
Synthetic quinolone that is a broad-spectrum bactericidal agent. Inhibits DNA-gyrase, topoisomerase II, an enzyme necessary
for bacterial replication, transcription, repair, and recombination.
Effective against gram-positive and gram-negative bacteria.
Acute bacterial exacerbation of chronic bronchitis; acute sinusitis; community-acquired pneumonia; uncomplicated or complicated
UTI; pyelonephritis; gonorrhea due to susceptible organisms.
Hypersensitivity to gatifloxacin or other quinolone antibiotics; diabetes mellitus; viral infections; pregnancy (category
C); lactation. Safety and efficacy in children <18 y are unknown. Ophthalmic use in infants <1 mo.
Patients with CNS disorders including seizures or epilepsy; myasthenia gravis; GI disorders, renal dysfunction; hypersensitivity
to other medications; concurrent administration of aluminum-containing antacids.
Route & Dosage
|Acute Bacterial Exacerbation of Chronic Bronchitis, Complicated
Adult: PO 400 mg q.d. x 5 d
Complicated UTI, Acute Pyelonephritis
Adult: PO 400 mg q.d. x 710 d
Adult: PO 400 mg q.d. x 10 d
Adult: PO 400 mg q.d. x 714 d
Adult: PO 400 mg as a single dose or 200 mg q.d. x 3 d
Adult: PO 400 mg as a single dose
Clcr <40 mL/min or on dialysis: 400 mg x 1 d, then 200 mg q.d.
- Give at least 4 h before or after an aluminum- or magnesium-containing antacid, or iron-containing products.
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)Body as a Whole:
Headache, allergic reactions, chills, fever; back pain, chest pain. CNS:
Dizziness, abnormal dreams, insomnia
, paresthesia, tremor, vasodilatation, vertigo. CV:
Palpitation; peripheral edema. GI:
Nausea, diarrhea, abdominal pain, constipation
, dyspepsia, glossitis, oral moniliasis, stomatitis, vomiting. Respiratory:
Dyspnea, pharyngitis. Skin:
Rash, sweating. Urogenital: Vaginitis
, dysuria, hematuria. Special Senses:
Abnormal vision, taste perversion, tinnitus. Metabolic:
Diagnostic Test Interference
May cause false positive on opiate screening tests.
decreases elimination of gatifloxacin; ferrous sulfate, ALUMINUM
- or MAGNESIUM
reduce absorption of gatifloxacin; gatifloxacin
may cause slight increase in digoxin
96% from GI tract. Peak:
12 h PO. Distribution:
20% protein bound. Metabolism:
Minimal metabolism (<1%). Elimination:
Primarily in urine. Half-Life:
714 h (up to 3540 h in severe renal failure).
Assessment & Drug Effects
- Monitor for S&S of CNS disturbance especially with history of cerebrovascular disease or seizures.
- Lab tests: C&S prior to initiation of therapy; WBC with differential.
- Monitor diabetics for loss of glycemic control.
- Monitor for changes in digoxin blood levels with coadministered drugs.
Patient & Family Education
- Be aware that increased risk of seizures are associated with drug use in patient with history of seizures.
- Report unexplained dizziness or problems with balance, tendon pain, severe diarrhea, skin rash, mental status changes.